ArticleRevista da Associacao Medica Brasileira (1992)2026
Sarcopenia, its components and fracture risk in people living with human immunodeficiency virus.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the relationship between sarcopenia and its components with fracture risk in people living with human immunodeficiency virus, and to assess the association with sociodemographic and clinical characteristics.
methodsThis cross-sectional study was conducted with people living with human immunodeficiency virus undergoing antiretroviral therapy in the state of Mato Grosso do Sul, Brazil. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People criteria, assessing muscle strength (handgrip strength), skeletal muscle mass (skeletal muscle mass index), and physical performance (gait speed). The 10-year risk of major osteoporotic and hip fracture was estimated using the Brazilian version of the Fracture Risk Assessment Tool (FRAX®). Statistical analyses included chi-square tests, analysis of variance, and Spearman correlation (p<0.05).
resultsAmong 105 participants (44.6±13.5 years), the prevalence of confirmed or severe sarcopenia was 6.7%. No association was found between sarcopenia and the risk of major fracture (p=0.471) or hip fracture (p=0.254). However, handgrip strength was correlated with the risk of major fracture (ρ=-0.21; p=0.029) and hip fracture (ρ=-0.25; p=0.010). SMII showed moderate correlations with major fracture risk (ρ=-0.44; p<0.01) and hip fracture risk (ρ=-0.52; p<0.01). Gait speed was correlated only with hip fracture risk (ρ=-0.22; p=0.025). Older age (p<0.001) and lower body mass index (p=0.011) were significant risk factors.
conclusionSarcopenia as a categorical diagnosis was not associated with fracture risk, whereas lower handgrip strength and skeletal muscle mass index were associated with higher FRAX® estimates, and gait speed only with hip fracture risk. These findings support assessing sarcopenia-related parameters in people living with human immunodeficiency virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.